{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:38:52Z","timestamp":1770896332023,"version":"3.50.1"},"publisher-location":"Cham","reference-count":108,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319442501","type":"print"},{"value":"9783319442518","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/5584_2016_36","type":"book-chapter","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T05:12:34Z","timestamp":1481519554000},"page":"149-166","source":"Crossref","is-referenced-by-count":41,"title":["The Role of Beta-Blockers in the Treatment of Hypertension"],"prefix":"10.1007","author":[{"given":"John M.","family":"Cruickshank","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"36_CR1","doi-asserted-by":"publisher","unstructured":"Al-Wadei HA, Al-wadei MH, Schuller HM (2012) Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS One 7:e29915. Epub 2012","DOI":"10.1371\/journal.pone.0029915"},{"key":"36_CR2","first-page":"232","volume":"8","author":"MJ Barnes","year":"2014","unstructured":"Barnes MJ, McDougal DH (2014) Leptin into the rostral ventral lateral medulla (RVLM) augments renal sympathetic nerve activity and blood pressure. Front Neurosci 8:232","journal-title":"Front Neurosci"},{"key":"36_CR3","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","volume":"29","author":"TL Barron","year":"2011","unstructured":"Barron TL, Conolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta-blockers and breast cancer mortality: a population-based study. J Clin Oncol 29:2635\u20132644","journal-title":"J Clin Oncol"},{"key":"36_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.0954-6820.1986.tb02790.x","volume":"220","author":"G Berglund","year":"1986","unstructured":"Berglund G, Andersin O, Widgren B (1986) Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. Acta Med Scand 220:419\u2013424","journal-title":"Acta Med Scand"},{"key":"36_CR5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","volume":"289","author":"HR Black","year":"2003","unstructured":"Black HR, Elliot WJ, Grandits G, Grambcsh P, Lucente T, White WB et al (2003) Principal results of the Controlled Onset Verapamil Investigation Of Cardiovascular End Points (CONVINCE) Trial. JAMA 289:2073\u20132082","journal-title":"JAMA"},{"key":"36_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.autneu.2014.11.006","volume":"187","author":"VL Brooks","year":"2015","unstructured":"Brooks VL, Shi Z, Holwerda SW, Fadel PJ (2015) Obesity-induced increases in sympathetic nerve activity: sex matters. Auton Neurosci 187:18\u201326. doi:\n                    10.1016\/j.Autoneu.2014.11.006\n                    \n                  , Epub 2014 Nov 20","journal-title":"Auton Neurosci"},{"key":"36_CR7","first-page":"153","volume":"21","author":"Y Cakir","year":"2002","unstructured":"Cakir Y, Plummer HK, Tithof PK, Schuller HM (2002) Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 21:153\u2013157","journal-title":"Int J Oncol"},{"key":"36_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ijcard.2014.04.204","volume":"174","author":"AJS Coats","year":"2014","unstructured":"Coats AJS, Cruickshank JM (2014) Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications. Int J Cardiol 174:702\u2013709","journal-title":"Int J Cardiol"},{"key":"36_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18:1201\u20131206","journal-title":"Clin Cancer Res"},{"key":"36_CR10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","volume":"293","author":"J Coope","year":"1986","unstructured":"Coope J, Warrender TS (1986) Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 293:1145\u20131151","journal-title":"BMJ"},{"key":"36_CR11","volume-title":"Essential hypertension","author":"JM Cruickshank","year":"2013","unstructured":"Cruickshank JM (2013) Essential hypertension. People\u2019s Publishing House, Shelton"},{"key":"36_CR12","doi-asserted-by":"publisher","unstructured":"Cruickshank JM (2014) The unholy alliance between obesity, type-2 diabetes, the sympathetic nervous system, and hypertension in young\/middle-aged subjects. J Mol Genet Med S1. \n                    http:\/\/dd.org\/10.4172\/1747-0862.S1-016","DOI":"10.4172\/1747-0862.S1-016"},{"key":"36_CR13","unstructured":"Cruickshank JM, Prichard BNC (1994) Beta-blockers in clinical practice (2nd edn). Churchill Livingstone, Edinburgh, pp 1\u2013351"},{"key":"36_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1056\/NEJM197609092951101","volume":"295","author":"PE Cryer","year":"1976","unstructured":"Cryer PE, Haymond MW, Satiago JV, Shar SP (1976) Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 295:573\u2013577","journal-title":"N Engl J Med"},{"key":"36_CR15","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","volume":"338","author":"B Dahlof","year":"1991","unstructured":"Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO (1991) Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 338:1281\u20131285","journal-title":"Lancet"},{"key":"36_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al (2002) LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995\u20131003","journal-title":"Lancet"},{"key":"36_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahlof","year":"2005","unstructured":"Dahlof B, Sever PS, Poulter NR et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandanavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895\u2013906","journal-title":"Lancet"},{"key":"36_CR18","first-page":"11","volume":"103","author":"V Giorgi De","year":"2012","unstructured":"De Giorgi V, Gandini S, Grazzini M, Benemai S, Marchionni N, Geppetti P (2012) Beta-blockers: a new and emerging treatment for melanoma. Recenti Prog Med 103:11\u201316","journal-title":"Recenti Prog Med"},{"key":"36_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00004872-200204000-00037","volume":"20","author":"AJ Deary","year":"2002","unstructured":"Deary AJ, Schumann AL, Murfeet H, Haydock SF, Foo RS, Brown MJ (2002) Double-blind, placebo controlled crossover comparison of 5 classes of drugs. J Hypertens 20:771\u2013777","journal-title":"J Hypertens"},{"key":"36_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/CIRCULATIONAHA.106.668921","volume":"115","author":"JS Druktenis","year":"2007","unstructured":"Druktenis JS, Roman MJ, Fabsitz RR, Lee ET, Best LG, Russel M et al (2007) Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults. The Strong Heart Study. Circulation 115:221\u2013227","journal-title":"Circulation"},{"key":"36_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000107813","volume":"5","author":"S Eriksson","year":"1995","unstructured":"Eriksson S, Olofsson B-O, Wester P-O, for the TEST Study Group (1995) Atenolol in secondary prevention after stroke. Cerebrovasc Dis 5:21\u201325","journal-title":"Cerebrovasc Dis"},{"issue":"3","key":"36_CR22","first-page":"S123","volume":"2","author":"MO Esler","year":"1984","unstructured":"Esler MO, Jennings GL, Johns J, Burke F, Little PJ, Leonard P (1984) Estimation of \u201ctotal\u201d renal, cardiac and splanchnic sympathetic nervous tone in essential hypertension from measurements of noradrenaline release. J Hypertens Suppl 2(3):S123\u2013S125","journal-title":"J Hypertens Suppl"},{"key":"36_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"RO Estacio","year":"1998","unstructured":"Estacio RO, Jeffers BW, Hiatt W, Biggerstaff SL, Gifford N, Schrier RW (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645\u2013652","journal-title":"N Engl J Med"},{"key":"36_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJM198403293101303","volume":"310","author":"RD Feldman","year":"1984","unstructured":"Feldman RD, Limbird LE, Nadeau J, Robertson D, Wood AJ (1984) Alteration in leukocyte beta-receptor affinity with aging. A potential explanation for altered beta-adrenergic sensitivity in the elderly. N Engl J Med 310:815\u2013819","journal-title":"N Engl J Med"},{"key":"36_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/CLEP.S33695","volume":"4","author":"PJ Fitzgerald","year":"2012","unstructured":"Fitzgerald PJ (2012) Beta-blockers, norepinephrine, and cancer: an epidemiological viewpoint. Clin Epidemiol 4:151\u2013156","journal-title":"Clin Epidemiol"},{"key":"36_CR26","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/00004872-200018120-00023","volume":"18","author":"R Fogari","year":"2000","unstructured":"Fogari R, Zoppi A, Coradi L, Preti P, Malalamani GD, Muellini A (2000) Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens 18:1871\u20131875","journal-title":"J Hypertens"},{"key":"36_CR27","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/01.CIR.0000157159.39889.EC","volume":"111","author":"SS Franklin","year":"2005","unstructured":"Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS et al (2005) Predictors of new-onset diastolic and systolic hypertension. The Framingham Heart Study. Circulation 111:1121\u20131127","journal-title":"Circulation"},{"key":"36_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/j.1552-4604.1995.tb05009.x","volume":"35","author":"WH Frishman","year":"1995","unstructured":"Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS et al (1995) First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorthiazide in patients with stage 1 and stage 11 systemic hypertension. J Clin Pharmacol 35:182\u2013188","journal-title":"J Clin Pharmacol"},{"key":"36_CR29","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/0002-8703(93)90128-V","volume":"125","author":"MW Gillman","year":"1993","unstructured":"Gillman MW, Kannel WB, Belanger A (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 125:1148\u20131154","journal-title":"Am Heart J"},{"key":"36_CR30","first-page":"236","volume":"22","author":"G Grassi","year":"2004","unstructured":"Grassi G, Dell Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G (2004) Effect of central and peripheral body fat distribution on sympathetic and baroreflex functionin obese normotensives. J Hypertens 22:236\u2013239","journal-title":"J Hypertens"},{"key":"36_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/pros.22564","volume":"73","author":"HH Grytli","year":"2013","unstructured":"Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Hanheim LL (2013) Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 73:250\u2013260","journal-title":"Prostate"},{"key":"36_CR32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type-2 diabetes. N Engl J Med 364:907\u2013917","journal-title":"N Engl J Med"},{"key":"36_CR33","first-page":"189","volume":"20","author":"JJ Hammond","year":"1978","unstructured":"Hammond JJ, Kirkendall WM, Zama A, Thomas JC, Overturf ML (1978) Pindolol, propranolol and chlorthalidone in moderate hypertension. Pharmacologist 20:189","journal-title":"Pharmacologist"},{"key":"36_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Linholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al (1999a) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project(CAPP)randomised trial. Lancet 353:611\u2013616","journal-title":"Lancet"},{"key":"36_CR35","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B et al (1999b) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751\u20131756","journal-title":"Lancet"},{"key":"36_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","volume":"356","author":"L Hansson","year":"2000","unstructured":"Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO et al (2000) Randomised of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality: the Nordic Diltiazem (NORDIL) study. Lancet 356:359\u2013365","journal-title":"Lancet"},{"key":"36_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/HJH.0000000000000770","volume":"34","author":"JL Harding","year":"2016","unstructured":"Harding JL, Sooriyakumaran M, Anstey KJ, Adam R, Balkau B, Brennan-Olsen S et al (2016) Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J Hypertens 34:149\u2013155","journal-title":"J Hypertens"},{"key":"36_CR38","first-page":"8","volume":"29","author":"EC Hart","year":"2014","unstructured":"Hart EC, Charkoudian N (2014) Sympathetic neural regulation of blood pressure: influence of sex and age. Physiology (Bethesda) 29:8\u201315","journal-title":"Physiology (Bethesda)"},{"key":"36_CR39","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/hc3801.096325","volume":"104","author":"UE Heidland","year":"2001","unstructured":"Heidland UE, Strauer BE (2001) Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104:1477\u20131482","journal-title":"Circulation"},{"key":"36_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0021-9150(70)90089-4","volume":"12","author":"P Helin","year":"1970","unstructured":"Helin P, Lorenzen I, Garbash C, Matthiessen ME (1970) Atheroscerosis in rabbit aorta induced by noradrenaline. The importance of the duration of noradrenaline action. Atherosclerosis 12:125\u2013132","journal-title":"Atherosclerosis"},{"key":"36_CR41","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0895-7061(03)00917-8","volume":"16","author":"K Heuser","year":"2003","unstructured":"Heuser K, Vitkovsky J, Raasch W, Schmieder R, Schobel HP (2003) Elevation of sympathetic activity by eprosartan in young male subjects. Am J Hypertens 16:658\u2013664","journal-title":"Am J Hypertens"},{"issue":"3","key":"36_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.amjhyper.2006.09.006","volume":"20","author":"TP Hiltunen","year":"2007","unstructured":"Hiltunen TP, Suonsyrja T, Hanilla-Handelberg T, Paarvonen KJ, Miettinen HE, Strandberg T et al (2007) Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomesed, cross-over study with foue antihypertensive drugs (The GENRES Study). Am J Hypertens 20(3):311\u2013318","journal-title":"Am J Hypertens"},{"key":"36_CR43","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type-2 diabetes. N Engl J Med 359:1565\u20131576","journal-title":"N Engl J Med"},{"key":"36_CR44","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1161\/01.CIR.0000103123.66264.FE","volume":"108","author":"RJ Huggett","year":"2003","unstructured":"Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Macintosh AF, Mary DA (2003) Impact of type-2 diabetes on sympathetic neural mechanisms in hypertension. Circulation 108:3097\u20134101","journal-title":"Circulation"},{"key":"36_CR45","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Hanada M et al (2011) Effects of olmesartan on renal and cardiovascular outcomes in type-2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54:2978\u20132986","journal-title":"Diabetologia"},{"key":"36_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1506699","volume":"374","author":"TH Inge","year":"2016","unstructured":"Inge TH, Courcoulas AP, Jenkins TM, Michalski MP, Helmrath MA, Brandt MD et al (2016) Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 374:113\u2013123","journal-title":"N Engl J Med"},{"key":"36_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507\u2013520","journal-title":"JAMA"},{"key":"36_CR48","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1503\/cmaj.060110","volume":"174","author":"N Khan","year":"2006","unstructured":"Khan N, McAlister FA (2006) Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 174:1737\u20131742","journal-title":"CMAJ"},{"issue":"5","key":"36_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0828-282X(09)70492-1","volume":"25","author":"NA Khan","year":"2009","unstructured":"Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA et al (2009) The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 \u2013 therapy. Can J Cardiol 25(5):287\u2013298","journal-title":"Can J Cardiol"},{"key":"36_CR50","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/01.hjh.0000468636.90353.f5","volume":"33","author":"V Kostis","year":"2015","unstructured":"Kostis V, Nilsson P, Grassi G, Mancia G, Redon J, Luft F et al (2015) New developments in the pathogenesis of obesity-induced hypertension. J Hypertens 33:1499\u20131508","journal-title":"J Hypertens"},{"key":"36_CR51","doi-asserted-by":"publisher","unstructured":"Krause T, Lovibond K, Caufield M, McCormak T, Williams B (2011) Management of hypertension: summary of NICE guidelines. BMJ 343:d4891.doi:\n                    10.1136\/bmj:d4891","DOI":"10.1136\/bmj:d4891"},{"issue":"suppl 5","key":"36_CR52","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.cjca.2014.01.006","volume":"30","author":"LM Kuyper","year":"2014","unstructured":"Kuyper LM, Kahn NA (2014) Atenolol vs non-atenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 30(suppl 5):S47\u2013S53","journal-title":"Can J Cardiol"},{"key":"36_CR53","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/HYPERTENSIONAHA.107.094649","volume":"50","author":"E Lambert","year":"2007","unstructured":"Lambert E, Straznicky N, Schlaich M, Esler MP, Haikerwal D, Brencley D et al (2007) Differing pattern of sympathoexcitation in normal- weight and obesity-related hypertension. Hypertension 50:862\u2013868","journal-title":"Hypertension"},{"key":"36_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0002-9343(86)90153-1","volume":"80","author":"P Leren","year":"1986","unstructured":"Leren P, Heigeland A (1986) Coronary heart disease and treatment of hypertension. The Oslo Study. Am J Med 80:3\u20136","journal-title":"Am J Med"},{"key":"36_CR55","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","volume":"366","author":"LH Lindholm","year":"2005","unstructured":"Lindholm LH, Carlberg B, Samuelsson O (2005) Should beta-blockers remain the first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545\u20131553","journal-title":"Lancet"},{"key":"36_CR56","first-page":"1462","volume":"28","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifcova R, Fagard R, Gernano G et al (2007) 2007 Guidelines forthe management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462\u20131536","journal-title":"Eur Heart J"},{"key":"36_CR57","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","volume":"291","author":"Medical Research Working Party","year":"1985","unstructured":"Medical Research Working Party (1985) MRC trial of treatment of mild hypertension: principle results. BMJ 291:97\u2013104","journal-title":"BMJ"},{"key":"36_CR58","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","volume":"29","author":"A Melhem-Bertrandt","year":"2011","unstructured":"Melhem-Bertrandt A, Chavez-Macgreggor LX, Brown EN, Lee RT, Meric-Bernstam F et al (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645\u20132652","journal-title":"J Clin Oncol"},{"key":"36_CR59","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1210\/jc.2008-2660","volume":"94","author":"DV Menon","year":"2009","unstructured":"Menon DV, Arbique D, Wang Z, Adam-Huet B, Auchus RJ, Vongpatanasin W (2009) Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab 94:1361\u20131366","journal-title":"J Clin Endocrinol Metab"},{"key":"36_CR60","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.amjcard.2009.08.674","volume":"105","author":"E Moltzer","year":"2010","unstructured":"Moltzer E, Mattace Raso FU, Karamermer Y, Boersma E, Webb GD, Simoons ML et al (2010) Comparison of candesartan versus metoprolol for treatment of systemic hypertension after repaired aortic coarctation. Am J Cardiol 105:217\u2013222","journal-title":"Am J Cardiol"},{"key":"36_CR61","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","volume":"304","author":"MRC Working Party","year":"1992","unstructured":"MRC Working Party (1992) Medical Research Council trial of treatment of hypertension in older adults.: principal results. BMJ 304:405\u2013412","journal-title":"BMJ"},{"key":"36_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0002-9343(93)90181-N","volume":"94","author":"JM Neutel","year":"1993","unstructured":"Neutel JM, Smith DH, Ram CV, Kaplan NM, Papademetriou V, Fagan TC et al (1993) Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 94:181\u2013187","journal-title":"Am J Med"},{"key":"36_CR63","unstructured":"No author listed (1980) The Australian therapeutic trial in hypertension. Report by the Management Committee. Lancet 1:1261\u20131267"},{"key":"36_CR64","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1161\/01.CIR.95.9.2286","volume":"95","author":"G Noll","year":"1997","unstructured":"Noll G, Wenzel RR, de Marchi S, Shaw S, Luscher TF (1997) Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation 95:2286\u20132292","journal-title":"Circulation"},{"key":"36_CR65","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","volume":"48","author":"K Norris","year":"2006","unstructured":"Norris K, Bourgoigne J, Gassman J, Hibert L, Middleton J, Phillips RA et al (2006) Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48:739\u2013751","journal-title":"Am J Kidney Dis"},{"key":"36_CR66","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11906-009-0035-4","volume":"11","author":"P Palatini","year":"2009","unstructured":"Palatini P, Julius S (2009) The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr Hypertens Rep 11:199\u2013205","journal-title":"Curr Hypertens Rep"},{"key":"36_CR67","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/11315250-000000000-00000","volume":"29","author":"G Parrinello","year":"2009","unstructured":"Parrinello G, Paterna S, Torres D, Di Pasquale P, Mezzero M, La Rocca G et al (2009) One year renal and cardiac effect of bisoprolol versus losartan in recently diagnosed hypertensive patients. Clin Drug Investig 29:591\u2013600","journal-title":"Clin Drug Investig"},{"key":"36_CR68","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/bjc.2013.205","volume":"108","author":"E Pasquier","year":"2013","unstructured":"Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J et al (2013) Beta-blockers increase response to chemotherapy via direct anti-tumor and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer 108:2485\u20132494","journal-title":"Br J Cancer"},{"key":"36_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1440-1681.2006.04350.x","volume":"33","author":"Y-X Peng","year":"2006","unstructured":"Peng Y-X, Shan J, Qi XY, Qi XY, Zhang SJ, Ma SP, Wang N et al (2006) The catecholamine-beta-adrenoceptor-cAMP system and prediction of cardiovascular events in hypertension. Clin Exp Pharmacol Physiol 33:27\u2013231","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"36_CR70","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"CJ Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. JAMA 290:2805\u20132816","journal-title":"JAMA"},{"key":"36_CR71","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","volume":"15","author":"L Perron","year":"2004","unstructured":"Perron L, Bairati L, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15:535\u2013541","journal-title":"Cancer Causes Control"},{"key":"36_CR72","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000163851","volume":"75","author":"MG Perrone","year":"2008","unstructured":"Perrone MG, Notanicola M, Caruso MG, Tutino V, Scilimati A (2008) Upregulation of beta-3adrenergic receptor mRNA in human colon cancer: a preliminary study. Oncology 75:224\u2013229","journal-title":"Oncology"},{"key":"36_CR73","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/j.1552-4604.1996.tb04752.x","volume":"36","author":"LM Prisant","year":"1996","unstructured":"Prisant LM, Mensah GA (1996) Use of beta-adrenergic receptor blockers in blacks. J Clin Pharmacol 36:867\u2013873","journal-title":"J Clin Pharmacol"},{"key":"36_CR74","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"Prospective Studies Collaboration","year":"2002","unstructured":"Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903\u20131913","journal-title":"Lancet"},{"key":"36_CR75","first-page":"541","volume":"19","author":"OJ Robb","year":"1985","unstructured":"Robb OJ, Petrie JC, Webster J, Harry J (1985) ICI 118,551 does not reduce blood pressure in hypertensive patients responsive to atenolol and propranolol. Br J Clin Pharmacol 19:541\u2013542","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"36_CR76","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1097\/HJH.0000000000000567","volume":"33","author":"G Seravalle","year":"2015","unstructured":"Seravalle G, Lonati L, Buzzi S, Cairo M, Quarti Trevano F, Dell\u2019Oro R et al (2015) Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states. J Hypertens 33(7):1411\u20131417. doi:\n                    10.1097\/HJH.000000000000567","journal-title":"J Hypertens"},{"key":"36_CR77","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","unstructured":"SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265:3255\u20133264","journal-title":"JAMA"},{"key":"36_CR78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/0003-4819-147-1-200707030-00003","volume":"147","author":"I Sipahi","year":"2007","unstructured":"Sipahi I, Tuzcu M, Wolski KE, Nicholls SJ, Schoenhagen P, Hu B et al (2007) Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Am Int Med 147:10\u201318","journal-title":"Am Int Med"},{"key":"36_CR79","first-page":"126","volume":"13","author":"C Smith","year":"1999","unstructured":"Smith C, Teitler M (1999) Beta-blocker selectivity at cloned human beta-1 and beta-2 adrenergic receptors. Carsiovasc Drugs Ther 13:126\u2013127","journal-title":"Carsiovasc Drugs Ther"},{"key":"36_CR80","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1067\/mlc.2000.106453","volume":"135","author":"JR Sowers","year":"2000","unstructured":"Sowers JR, Lester M (2000) Hypertension, hormones and aging. J Lab Clin Med 135:379\u2013386","journal-title":"J Lab Clin Med"},{"key":"36_CR81","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0140-6736(07)61034-4","volume":"370","author":"MH Straus","year":"2007","unstructured":"Straus MH, Hall AS (2007) Renin-angiotensin system and cardiovascular talk. Lancet 370:23\u201324","journal-title":"Lancet"},{"key":"36_CR82","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","volume":"114","author":"MH Strauss","year":"2006","unstructured":"Strauss MH, Hall AS (2006) Angiotensin receptor blockers may increase the risk of myocardial infarction. Circulation 114:838\u2013854","journal-title":"Circulation"},{"key":"36_CR83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/PL00012092","volume":"6","author":"T Takezaki","year":"2001","unstructured":"Takezaki T, Hamajima N, Maisuo K, Tanaka R, Hirai T, Kato T et al (2001) Association of polymorphisms in the beta-2 and beta-3 adrenoceptor genes with risk of colorectal cancer in Japanese. Int J Clin Oncol 6:117\u2013122","journal-title":"Int J Clin Oncol"},{"key":"36_CR84","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1097\/00000542-199106000-00011","volume":"74","author":"J Tarnow","year":"1991","unstructured":"Tarnow J, Muller RK (1991) Cardiovascular effects of low-dose epinephrine infusions in relation to the extent of pre-operative beta-blockade. Anaesthesiology 74:1035\u20131043","journal-title":"Anaesthesiology"},{"key":"36_CR85","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/00005344-199011000-00003","volume":"16","author":"DM Tenero","year":"1990","unstructured":"Tenero DM, Bottorf MB, Burlew BS, Williams JB, Lalande RL (1990) Altered beta-adrenergic sensitivity and protein binding to I-propranolol in the elderly. Cardiovasc Pharmacol 16:702\u2013707","journal-title":"Cardiovasc Pharmacol"},{"key":"36_CR86","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomised to ACE-inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981\u20132997","journal-title":"JAMA"},{"key":"36_CR87","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","volume":"3","author":"The IPPPSH Collaborative Group","year":"1985","unstructured":"The IPPPSH Collaborative Group (1985) Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the International prospective primary prevention study in hypertension (IPPPSH). J Hypertens 3:379\u2013392","journal-title":"J Hypertens"},{"key":"36_CR88","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","volume":"33","author":"C Thomopoulos","year":"2015","unstructured":"Thomopoulos C, Parati G, Zanchetti A (2015a) Effects of blood pressure-lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs \u2013Overview and meta-analysis. J Hypertens 33:195\u2013211","journal-title":"J Hypertens"},{"key":"36_CR89","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/HJH.0000000000000447","volume":"33","author":"C Thomopoulos","year":"2015","unstructured":"Thomopoulos C, Parati G, Zanchetti A (2015b) Effects of blood pressure-lowering on outcome incidence in hypertension: head-to-head comparisons of various classes of antihypertensive drugs \u2013 overview and meta-analyses. J Hypertens 33:1321\u20131341","journal-title":"J Hypertens"},{"key":"36_CR90","doi-asserted-by":"publisher","unstructured":"Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling stroke. The Dutch TIA Trial Study Group. Stroke 24:543\u2013548 (1993)","DOI":"10.1161\/01.STR.24.4.543"},{"key":"36_CR91","doi-asserted-by":"publisher","unstructured":"U.K. Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes. UKPDS 38. BMJ 317:703\u2013713","DOI":"10.1136\/bmj.317.7160.703"},{"key":"36_CR92","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril reducing risk of macrovascular and microvascular complications of type-2 diabetes: UKPDS 39. BMJ 317:713\u2013720","journal-title":"BMJ"},{"key":"36_CR93","doi-asserted-by":"publisher","unstructured":"Veterans Administration Cooperative Study Group on Antihypertensive Agents (1982) Comparison of propranolol and hydrochlorthiazide for the initial treatment of hypertension. Results of long-term therapy. JAMA 248:2004\u20132011","DOI":"10.1001\/jama.1982.03330160052024"},{"key":"36_CR94","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0735-1097(96)00122-2","volume":"28","author":"T Armin von","year":"1996","unstructured":"von Armin T, for the TIBBS Investigators (1996) Prognostic significance of transient ischemic episodes: response to treatment shows improve prognosis. J Am Coll Cardiol 28:20\u201324","journal-title":"J Am Coll Cardiol"},{"key":"36_CR95","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/carcin\/22.3.473","volume":"22","author":"D Weddle","year":"2001","unstructured":"Weddle D, Tiihoff P, Williams M, Schuller HM (2001) Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 22:473\u2013479","journal-title":"Carcinogenesis"},{"issue":"Suppl","key":"36_CR96","first-page":"S36","volume":"8","author":"A Wellstein","year":"1986","unstructured":"Wellstein A, Palm D, Belz GG (1986) Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol 8(Suppl):S36\u2013S40","journal-title":"J Cardiovasc Pharmacol"},{"key":"36_CR97","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/01.HYP.17.4.579","volume":"17","author":"J Wikstrand","year":"1991","unstructured":"Wikstrand J, Warnold T, Tuomilehto J, Olsson G, Barber HJ, Eliasson K et al (1991) Metoprolol versus diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 17:579\u2013588","journal-title":"Hypertension"},{"key":"36_CR98","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","volume":"5","author":"L Wilhelmsen","year":"1987","unstructured":"Wilhelmsen L, Bergland G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J et al (1987) Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 5:561\u2013572","journal-title":"J Hypertens"},{"key":"36_CR99","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.107.692970","volume":"115","author":"B Williams","year":"2007","unstructured":"Williams B (2007) The obese hypertensive. The weight of evidence against beta-blockers. Circulation 115:1973\u20131974","journal-title":"Circulation"},{"key":"36_CR100","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jama.2013.277510","volume":"310","author":"CS Wiysonge","year":"2013","unstructured":"Wiysonge CS, Opie LH (2013) Beta-blockers as initial therapy for hypertension. JAMA 310:1851\u20131852","journal-title":"JAMA"},{"key":"36_CR101","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright","year":"2002","unstructured":"Wright JT, Bakris GL, Green T (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288:2421\u20132431","journal-title":"JAMA"},{"key":"36_CR102","doi-asserted-by":"publisher","unstructured":"Wu H-Y, Huang J-W, Lin H-J, Liao WC, Peng YS, Hung KY et al (2013) Comparative effectiveness of renin-angiotensin system blockers and of other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 347:f6008. doi:\n                    10.1136\/bmj.f6008","DOI":"10.1136\/bmj.f6008"},{"key":"36_CR103","doi-asserted-by":"publisher","unstructured":"Xue H, Lu Z, Tang, WL, Pang LW, Wang GM, Wong GW et al (2015). First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 1:CD008170. doi:\n                    10.1002\/14651858.CD008170.pub2","DOI":"10.1002\/14651858.CD008170.pub2"},{"key":"36_CR104","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/01.HYP.13.6.870","volume":"13","author":"Y Yamada","year":"1989","unstructured":"Yamada Y, Miyajima E, Tochicubo O, Matsukawa T, Isshi M (1989) Age related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 13:870\u2013877","journal-title":"Hypertension"},{"issue":"S","key":"36_CR105","doi-asserted-by":"publisher","first-page":"182S","DOI":"10.1093\/ajh\/5.6.182S","volume":"6","author":"AP Yurenev","year":"1992","unstructured":"Yurenev AP, Dyakonova HG, Novikov ID (1992) Management of essential hypertension in patients with different degrees of left ventricular hyperterophy. Multicentre trial. Am J Hypertens 6(S):182S\u2013189S","journal-title":"Am J Hypertens"},{"key":"36_CR106","first-page":"111","volume":"53","author":"FJ Zacharias","year":"1977","unstructured":"Zacharias FJ, Cowen KJ (1977) Comparison of propranolol and atenolol in hypertension. Postgrad Med J 53:111\u2013113","journal-title":"Postgrad Med J"},{"key":"36_CR107","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","volume":"106","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A, Bond MG, Henning M, Neiss A, Mancia G, Dal Palu C et al (2002) Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randonised, double-blind, long-term trial. Circulation 106:2422\u20132427","journal-title":"Circulation"},{"key":"36_CR108","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4161\/cbt.10.1.11944","volume":"10","author":"D Zhang","year":"2010","unstructured":"Zhang D, Ma QY, Hu HT, Zhang M (2010) Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkB and AP-1. Cancer Biol Ther 10:19\u201329","journal-title":"Cancer Biol Ther"}],"container-title":["Advances in Experimental Medicine and Biology","Hypertension: from basic research to clinical practice"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2016_36","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T13:11:59Z","timestamp":1494335519000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/5584_2016_36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319442501","9783319442518"],"references-count":108,"URL":"https:\/\/doi.org\/10.1007\/5584_2016_36","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}